Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 3/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.32 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43278 | 0.75 | SMPD1 (0.34) | PGDPTPN1SMPD1PGK1PGK2 | |
| SCHEMBL2229219 | 0.74 | PTPN1 (0.39) | PGDPTPN1SMPD1PGK1PGK2 | |
| Phosphoric Acid SCHEMBL2148162 | 0.73 | SMPD1 (0.33) | PGDPTPN1SMPD1PGK1PGK2 | |
| SCHEMBL28301016 | 0.72 | SMPD1 (0.35) | PTPN1SMPD1LAP3PGK1PGK2 | |
| SCHEMBL31316283 | 0.72 | LAP3 (0.36) | PTPN1SMPD1LAP3PGK1PGK2 | |
| SCHEMBL2160083 | 0.71 | PGD (0.31) | PGD | |
| SCHEMBL8060226 | 0.71 | FDPS (0.37) | PGDPTPN1SMPD1PGK1PGK2 | |
| SCHEMBL183389 | 0.70 | SMPD1 (0.34) | SMPD1PGK1PGK2 | |
| SCHEMBL28302194 | 0.70 | SMPD1 (0.34) | PTPN1SMPD1LAP3 | |
| SCHEMBL4825537 | 0.68 | CA4 (0.35) | SMPD1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590446-B2 | Microorganism for simultaneously producing L-amino acid and riboflavin, and method for producing L-amino acid and riboflavin using same | CJ CHEILJEDANG CORPORATION (KR) | 2020-03-17 | — | — | US | disclosed |
| US-10245262-B2 | Immunological reagents and uses therefor | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-04-02 | — | — | US | disclosed |
| US-20170209442-A1 | IMMUNOLOGICAL REAGENTS AND USES THEREFOR | MONASH UNIVERSITY (AU) | 2017-07-27 | — | — | US | disclosed |
| WO-2015149130-A9 | IMMUNOLOGICAL REAGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015149130-A1 | IMMUNOLOGICAL REAGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-10-08 | — | — | WO | disclosed |
| US-20140356518-A1 | MICROORGANISM FOR SIMULTANEOUSLY PRODUCING L-AMINO ACID AND RIBOFLAVIN, AND METHOD FOR PRODUCING L-AMINO ACID AND RIBOFLAVIN USING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2014-12-04 | — | — | US | disclosed |
| EP-2787082-A1 | MICROORGANISM FOR SIMULTANEOUSLY PRODUCING L-AMINO ACID AND RIBOFLAVIN, AND METHOD FOR PRODUCING L-AMINO ACID AND RIBOFLAVIN USING SAME | Cj Cheiljedang Corporation (KR) | 2014-10-08 | — | — | EP | disclosed |
| EP-2540831-A2 | Transgenic plants with enhanced agronomic traits | Monsanto Technology, LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-1332207-B1 | TRANSFORMATION SYSTEMS FOR FLAVINOGENIC YEAST | ARCHER DANIELS MIDLAND CO (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-0405370-B2 | Riboflavinoverproducing strains of bacteria | DSM IP ASSETS BV (NL) | 2007-12-19 | — | — | EP | disclosed |
| US-6420135-B1 | POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCE INFORMATION STORED ON COMPUTER READABLE MEDIA | HUMAN GENOME SCIENCES, INC. | 2002-07-16 | — | — | US | disclosed |
| WO-2002006448-A2 | TRANSFORMATION SYSTEMS FOR FLAVINOGENIC YEAST | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| US-6322995-B1 | RECOMBINANT GRAM POSITIVE BACTERIUM USED FOR PRODUCING RIBOFLAVIN | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-27 | — | — | US | disclosed |
| EP-1051504-A2 | RIBOFLAVIN BIOSYNTHESIS GENES FROM PLANTS AND USES THEREOF | Novartis AG (CH) | 2000-11-15 | — | — | EP | disclosed |
| EP-0405370-B1 | Riboflavinoverproducing strains of bacteria | HOFFMANN LA ROCHE (CH) | 2000-08-30 | — | — | EP | disclosed |
| EP-1001026-A2 | Riboflavinoverproducing strains of bacteria | F. Hoffmann-La Roche AG (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999038986-A2 | RIBOFLAVIN BIOSYNTHESIS GENES FROM PLANTS AND USES THEREOF | NOVARTIS AG (CH) | 1999-08-05 | — | — | WO | disclosed |
| US-5925538-A | CULTURING RECOMBINANT BACTERIUM HAVING EXOGENOUS NUCLEIC ACID SEQUENCE CODING FOR PROMOTER AND OPEN READING FRAME 3 STRUCTURAL GENE SIMILAR TO A BACILLUS SUBTILIS RIBOFLAVIN OPERON GENE, RECOVERING AT LEAST 10 GRAMS PER LITER | ROCHE VITAMINS INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5837528-A | NUCLEOTIDE SEQUENCE OF RIB OPERON AND ITS OPEN READING FRAMES; GENETIC ENGINEERING | HOFFMANN LA ROCHE, INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0405370-A1 | Riboflavinoverproducing strains of bacteria | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10245262-B2 | Immunological reagents and uses therefor | CD81, MRGPRX2, MRGPRX1 | PGD 4645/4885PTPN1 1432/4885SMPD1 1362/4885 |
| US-20170209442-A1 | IMMUNOLOGICAL REAGENTS AND USES THEREFOR | CD81, MRGPRX2, MRGPRX1 | PGD 4645/4885PTPN1 1432/4885SMPD1 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.